Selection of patients for combination therapy
AssigneeSyndax Pharmaceuticals, Inc.
InventorsPeter ORDENTLICH, Lei WANG, Serap SANKOH, Michael MEYERS
Life of this patent
Estimating the term…
Abstract
Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising an HDAC inhibitor and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type which are CD14-positive, HLA-DR-high and/or CD16-negative, as a therapeutic indicator in the setting of HDAC inhibitor combination therapies.
Claims30
A method of selecting a patient for combination therapy comprising an HDAC inhibitor and second therapeutic agent comprising:
- providing a peripheral blood sample obtained from the patient, wherein the patient is diagnosed with a cancer;
- measuring the number of cells in the peripheral blood sample which are CD14-positive, HLA-DR-high, and/or CD16-negative;
- measuring the number of total peripheral blood mononuclear cells in the peripheral blood sample;
- and
- administering the combination therapy if the percentage of the CD14-positive, HLA-DR-high, and/or CD16-negative cells relative to total peripheral blood mononuclear cells is greater than a pre-determined percentage.
(canceled)
10-18. (canceled)
21-22. (canceled)
25-27. (canceled)
30-34. (canceled)
37-42. (canceled)
A method of selecting a patient for combination therapy comprising entinostat and second therapeutic agent comprising:
- providing a peripheral blood sample obtained from the patient, wherein the patient is diagnosed with a cancer;
- measuring the number of cells in the peripheral blood sample which are CD14-positive, HLA-DR-high and CD16-negative;
- measuring the number of total peripheral blood mononuclear cells in the peripheral blood sample;
- and
- administering the combination therapy if the percentage of the CD14-positive, HLA-DR-high and/or CD16-negative cells relative to total peripheral blood mononuclear cells is greater than a pre-determined percentage.
(canceled)
A method of selecting a patient for combination therapy comprising an entinostat and a second therapeutic agent comprising:
- providing a peripheral blood sample from the patient, wherein the patient is diagnosed with non-small cell lung cancer and/or melanoma and progressed on and/or was considered unresponsive to prior PD-1 or PD-L1 therapy;
- measuring the number of cells in the peripheral blood sample which are CD14-positive, HLA-DR-high, and CD16-negative;
- measuring the number of total peripheral blood mononuclear cells in the peripheral blood sample;
- and
- administering a combination therapy if the percentage of CD14-positive, HLA-DR-high, and CD16-negative cells relative to total live peripheral blood mononuclear cells is greater than a pre-determined percentage.
(canceled)
Dependencies are inferred from the claim text.